Tresiba® (insulin degludec) (NN1250)

:Type 1 and 2 diabetes
:Filed for registration

A new-generation basal insulin with ultra-long duration of action of more than 42 hours. Intended to offer a flexible treatment and a good safety profile. Approved in the EU and Japan and under regulatory review in the US and other major markets.

Company announcements
Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes (31 May 2013)
Increased operating profit by 18% in the first quarter of 2013 (01 May 2013)
Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® (10 Feb 2013)
Read more company announcements

Press releases
Novo Nordisk lancerer Tresiba® (insulin degludec) i Danmark (04 Mar 2013)
Tresiba® now ready to be launched in Japan (13 Feb 2013)
Novo Nordisk upgraded to ‘A1’ by Moody’s (05 Dec 2012)
Read more press releases

Scientific abstracts
Biochemistry (2013)
Diabetes Care (2011)
Diabetes Care (2011)
Read more scientific abstracts

You can search for more clinical trials on http://clinicaltrials.gov
  •